Clinical Trial Update: The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial (TG01/QS-21 vaccine) is evaluating a peptide vaccine with QS-21 adjuvant in high-risk smoldering multiple myeloma and multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• QS-21 adjuvant (QS-21 adjuvant)
• Tg01 Vaccine

Snippet

Sponsor: Oslo University Hospital | Conditions: Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING